Chelsea Therapeutics International Up 29.6% Since SmarTrend Uptrend Call (CHTP)
Comtex SmarTrend(R) - Thu Feb 12, 4:43PM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 13 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
29.6% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Thu Feb 05, 11:03AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 13 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Uptrend Call Working As Chelsea Therapeutics International Stock Rises 29.6% (CHTP)
Comtex SmarTrend(R) - Wed Jan 07, 11:05AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 12 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Shares of CHTP Up 29.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 31, 9:46AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 12 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 39.51 (+0.69), CHTP: 6.52 (-0.03), SUPN: 8.80 (+0.22), ITCI: 24.53 (+2.45), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03)
Chelsea Therapeutics International Shares Up 29.6% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Dec 16, 5:06PM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 11 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Chelsea Therapeutics International Has Returned 29.6% Since SmarTrend Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Dec 02, 9:43AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 11 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CHTP: 6.52 (-0.03), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), BCLI: 3.86 (-0.02), BSX: 14.98 (+0.24), IPXL: 39.51 (+0.69), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), CVTS: (), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), PRTA: 22.89 (+0.13), PRAN: 1.09 (-0.55), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)